Abbott Laboratories delivers with exceptional consistency — all four recent quarters within a fraction of a percent of consensus — and offers 18.3% headroom to the analyst price target with a roughly 4-to-1 favorable risk/reward; the principal headwinds are a confirmed price downtrend and an unusually extreme put/call ratio that warrants monitoring before adding exposure.
Thesis pillars
- Consistent Earnings Delivery Streak↑Improving
- Confirmed Price Downtrend Below 200ma↑Improving
- Extreme Put Call Ratio Hedge Demand↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 20, 2026
Abbott Laboratories (ABT) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $102.64, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.9%; Concentration risk — Geographic: international sales (61.0%).
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip.... Read more
Sell if holding. At $102.64, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.9%; Concentration risk — Geographic: international sales (61.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-10-29Recent Developments — Abbott Laboratories
Latest news
- NEWS Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance — Yahoo Finance negative
- NEWS Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - finance.yahoo.com — finance.yahoo.com negative
- NEWS Abbott (ABT) Stock May Be 25% Stretched After Biosensor Market Forecast - Simply Wall Street — Simply Wall Street negative
- NEWS Abbott Laboratories stock pre-market at EUR 89.14: plus 0.48 percent - AD HOC NEWS — AD HOC NEWS neutral
- NEWS Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st — simplywall.st positive
Generated 2026-10-29T11:14:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational sales61%10-K Item 1A: 'Sales outside of the U.S. in 2025 made up approximately 61 percent of Abbott's net sales'
Material Events(8-K, last 90d)
- 2026-04-27Item 5.02LOWKevin Conroy named to Abbott Board of Directors on April 24, 2026. Shareholders also approved 2026 Incentive Stock Program at Annual Meeting, replacing the 2017 Program. Routine board appointment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $102.64, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.9%; Concentration risk — Geographic: international sales (61.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $96.56. Score 5.4/10, moderate confidence.
Analyst target: $106.67 (+3.9% upside). Prior stop was $96.56. Stop-loss: $96.56.
Concentration risk — Geographic: international sales (61.0%); Thin upside margin: 3.9%; Negative news sentiment (-0.58).
Abbott Laboratories trades at a P/E of 38.2 (forward 17.3). TrendMatrix value score: 5.2/10. Verdict: Sell.
32 analysts cover ABT with a consensus score of 4.2/5. Average price target: $119.
What does Abbott Laboratories do?Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established...
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip. Approximately 61% of net sales came from outside the United States in 2025, with roughly 115,000 employees serving customers in more than 160 countries.